Skip to main content

Table 2 Change in primary and secondary outcomes between baseline and 12 months.

From: Methodological considerations for a randomised controlled trial of podiatry care in rheumatoid arthritis: lessons from an exploratory trial

 

Podiatry care (n = 16)

No podiatry care (n = 18)

  

Outcome

Change BL-12M

Change BL-12M

Difference (95% CI)*

p value

LFISIF (0–21)

0 (-3,1)

1 (0,3)

2 (0 to 4)

0.035

LFISAP (0–30)

0 (-4,2)

0 (-2,1)

0 (-2 to 3)

0.971

DAS (0–10)

0.2 (0,0.5)

0 (0,0.8)

0 (-0.4 to 0.4)

0.791

HAQ (0–3)

0 (-0.03,0)

0 (0,0.25)

0 (-0.12 to 0.33)

0.303

Walking speed (m/s)

0.01 (-0.01,0.07)

-0.02 (-0.20,0.02)

0 (-0.1 to 0)

0.411

  1. LFIS, Leeds Foot Impairment Score (IF, Impairment/footwear subscale, AP, Activity limitation/participation restriction subscale); DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; BL-12M, change in score between baseline and 12 months; CI, confidence interval. Values for the change in score from BL-12M are presented as the median (inter-quartile range). The between group difference in change scores was based on the Hodges-Lehman estimate of the median difference with 95% confidence interval based on a two-sided Mann-Whitney U-test.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us